MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3
- Yuewen Gao
- Zhaoyan Liu
- Zhaohong Ding
- Shicai Hou
- Jun Li
- Kehua Jiang
Published online on: February 7, 2018
Copyright: © Gao et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
To investigate the effect of microRNA (miR)-155 on colon cancer chemoresistance to cisplatine and its mechanism. Reverse transcription quantitative polymerase chain reaction was used to measure the levels of miR‑155 and forkhead box O3 (FOXO3) in colon cancer specimens and cell lines. Overexpression of miR‑155 and miR‑155 inhibitor were transfected into colon cancer cell lines to investigate its role of chemoresistance to cisplatin in colon cancer. MTS assays were used to analyse cell viability in vitro. In vivo tumor formation assays were performed in C57BL/6 wild type and miR‑155 knockout mice (miR‑155‑/‑). A luciferase reporter assay was used to measure the translation of FOXO3. Additionally, the expression of FOXO3 was detected by western blot analysis. It was identified that miR‑155 was markedly upregulated in colon cancer tissue and cell lines. Overexpression of miR‑155 enhanced colon cancer cell chemoresistance to cisplatin in vitro and tumorigenesis in vivo. In addition, overexpression of miR‑155 was associated with decreased levels of FOXO3, primarily through inhibiting the expression of FOXO3 to increase colon cancer resistanec to cisplatin. The present study demonstrated that miR‑155 increased colon cancer drug resistance and decreased FOXO3 expression in vivo and in vitro. This may provide a novel method for the treatment of drug‑resistant colon cancer.